small cell lung cancer

Amgen Clinches Clinical Wins in SCLC and Colorectal Cancer
Amgen Clinches Clinical Wins in SCLC and Colorectal Cancer
BioSpace
Amgen
oncology
colorectal cancer
small cell lung cancer
tarlatamab
Lumakras
Flag link:
Amgen's tarlatamab BiTEs at small cell lung cancer in brief readout
Amgen's tarlatamab BiTEs at small cell lung cancer in brief readout
Fierce Biotech
Amgen
tarlatamab
small cell lung cancer
T-cells
Flag link:
FDA approves Legend Biotech’s IND application for lung cancer therapy trial
FDA approves Legend Biotech’s IND application for lung cancer therapy trial
Clinical Trials Arena
FDA
Legend Biotech
LB2102
small cell lung cancer
Flag link:
FDA Keeps Jazz’s SCLC Treatment on the Market Despite Failed Confirmatory Trial
FDA Keeps Jazz’s SCLC Treatment on the Market Despite Failed Confirmatory Trial
BioSpace
Jazz Pharmaceuticals
FDA
Zepzelca
small cell lung cancer
Flag link:
FDA grants IND clearance for Phase I trials of Phanes’ cancer antibody
FDA grants IND clearance for Phase I trials of Phanes’ cancer antibody
Clinical Trials Arena
Phanes Therapeutics
PT217
FDA
small cell lung cancer
Flag link:
ESMO: Daiichi dazzles in lung cancer to dial up hopes for next ADC
ESMO: Daiichi dazzles in lung cancer to dial up hopes for next ADC
Fierce Biotech
ESMO
Daiichi Sankyo
DS-7300
small cell lung cancer
Flag link:
PhIII fail in overall survival measure clouds Ipsen's expansion plans for cancer drug Onivyde
PhIII fail in overall survival measure clouds Ipsen's expansion plans for cancer drug Onivyde
Endpoints
Ipsen
Onivyde
small cell lung cancer
clinical trials
Flag link:
Jazz recognizes less-common small cell lung cancer patients' needs with new online initiative
Jazz recognizes less-common small cell lung cancer patients' needs with new online initiative
Fierce Pharma
Jazz Pharmaceuticals
patient education
small cell lung cancer
Flag link:
Merck follows Bristol's suit, pulling Keytruda's SCLC nod. Is the FDA's accelerated approval reckoning finally here?
Merck follows Bristol's suit, pulling Keytruda's SCLC nod. Is the FDA's accelerated approval reckoning finally here?
Fierce Pharma
Merck
Keytruda
FDA
small cell lung cancer
Opdivo
Bristol-Myers Squibb
Flag link:
Jazz's $1B SCLC drug fails combo trial, quashing hopes of quick full approval
Jazz's $1B SCLC drug fails combo trial, quashing hopes of quick full approval
Endpoints
Jazz Pharmaceuticals
lurbinectedin
small cell lung cancer
clinical trials
Flag link:
Jazz Pharma’s $1B bet pays off with accelerated lung cancer approval
Jazz Pharma’s $1B bet pays off with accelerated lung cancer approval
Endpoints
Jazz Pharma
PharmaMar
FDA
Zepzelca
lurbinectedin
small cell lung cancer
Flag link:
Jazz targets US launch of SCLC drug after FDA grants fast review
Jazz targets US launch of SCLC drug after FDA grants fast review
Pharmaforum
PharmaMar
Jazz Pharmaceuticals
FDA
small cell lung cancer
lurbinectedin
priority review
Flag link:
United Therapeutics Drug Flunks Small Cell Lung Cancer Clinical Trial
United Therapeutics Drug Flunks Small Cell Lung Cancer Clinical Trial
Xconomy
United Therapeutics
clinical trials
Unituxin
small cell lung cancer
Flag link:
Merck’s Keytruda Shows Mixed Results in Lung Cancer Study
Merck’s Keytruda Shows Mixed Results in Lung Cancer Study
BioSpace
Merck
Keytruda
small cell lung cancer
Flag link:
PharmaMar files for FDA approval of small cell lung cancer drug
PharmaMar files for FDA approval of small cell lung cancer drug
Fierce Biotech
PharmaMar
FDA
lurbinectedin
small cell lung cancer
Flag link:
Zepsyre has a path to market at last
Zepsyre has a path to market at last
EP Vantage
PharmaMar
FDA
Zepsyre
small cell lung cancer
Flag link:
AstraZeneca’s Imfinzi gets FDA orphan drug status for small cell lung cancer
AstraZeneca’s Imfinzi gets FDA orphan drug status for small cell lung cancer
Pharmaceutical Business Review
AstraZeneca
Imfinzi
FDA
small cell lung cancer
orphan drugs
Flag link:
Bristol-Myers details its failure on Checkmate 451, highlighting a bleak future for their checkpoint combo
Bristol-Myers details its failure on Checkmate 451, highlighting a bleak future for their checkpoint combo
Endpoints
Bristol-Myers Squibb
Opdivo
Yervoy
small cell lung cancer
Flag link:
After ovarian cancer flop, PharmaMar's lurbinectedin makes the cut in small cell lung cancer
After ovarian cancer flop, PharmaMar's lurbinectedin makes the cut in small cell lung cancer
Endpoints
PharmaMar
ovarian cancer
lurbinectedin
relapsed small cell lung cancer
small cell lung cancer
Flag link:
Bristol Nabs Immunotherapy’s First FDA Nod for Small Cell Lung Cancer
Bristol Nabs Immunotherapy’s First FDA Nod for Small Cell Lung Cancer
Xconomy
FDA
Opdivo
Bristol-Myers Squibb
small cell lung cancer
Flag link:

Pages